Login / Signup

The European Network for the Study of Adrenal Tumors staging system (2015): a United States validation.

Letizia Maria Ippolita JannelloReha-Baris IncesuSimone MorraLukas ScheipnerAndrea BaudoMario de AngelisCarolin SiechZhe TianJordan A GoyalStefano LuzzagoFrancesco A MistrettaMatteo FerroFred SaadShahrokh F ShariatFelix K H ChunAlberto BrigantiDerya TilkiSascha AhyaiLuca CarmignaniNicola LongoOttavio de CobelliGennaro MusiPierre I Karakiewicz
Published in: The Journal of clinical endocrinology and metabolism (2024)
The accuracy of mENSAT is virtually the same as that of AJCC in predicting CSM (74.7 vs. 74.5%) and OM (73.7 vs. 73.5%). However, calibration is lower for mENSAT than for AJCC. In consequence, no obvious benefit appears to be associated with the use of mENSAT relative to AJCC in United States ACC patients.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • prognostic factors
  • lymph node